Patents by Inventor Xiufang Zheng

Xiufang Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200109144
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: August 2, 2019
    Publication date: April 9, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Chungen Liang, Jianping Wang, Kun Miao, Hongying Yun, Xiufang Zheng
  • Patent number: 10590146
    Abstract: The present invention relates to compounds of formula (I), wherein R1 to R4 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: March 17, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Lisha Wang, Hongying Yun, Xiufang Zheng
  • Patent number: 10399983
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: September 3, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Chungen Liang, Jianping Wang, Kun Miao, Hongying Yun, Xiufang Zheng
  • Publication number: 20190256515
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: January 29, 2019
    Publication date: August 22, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lu Gao, Chungen Liang, Hongying Yun, Xiufang Zheng, Jianping Wang, Kun Miao, Bo Zhang
  • Publication number: 20190169222
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: July 2, 2018
    Publication date: June 6, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Dongdong Chen, Song Feng, Lu Gao, Chao Li, Baoxia Wang, Lisha Wang, Hongying Yun, Xiufang Zheng
  • Patent number: 10233184
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: March 19, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Lu Gao, Chungen Liang, Hongying Yun, Xiufang Zheng, Jianping Wang, Kun Miao, Bo Zhang
  • Patent number: 10189838
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, W1, W2, W3, A and X are as described herein, compositions including the compounds and methods of using the compounds for the treatment and prophylaxis of respiratory syncytial virus infection.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: January 29, 2019
    Assignee: Hoffman-La Roche Inc.
    Inventors: Lisha Wang, Lu Gao, Mengwei Huang, Lei Guo, Chungen Liang, Wei Zhu, Song Feng, Xiufang Zheng, Weixing Zhang, Guolong Wu, Baoxia Wang, Hongying Yun
  • Patent number: 10065973
    Abstract: The present invention relates to compounds of formula (I), wherein R1 to R5 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: September 4, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Baoxia Wang, Lisha Wang, Hongying Yun, Xiufang Zheng
  • Patent number: 10040815
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: August 7, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Dongdong Chen, Song Feng, Lu Gao, Chao Li, Baoxia Wang, Lisha Wang, Hongying Yun, Xiufang Zheng
  • Publication number: 20180118763
    Abstract: The present invention relates to compounds of formula (I), wherein R1 to R4 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: December 22, 2017
    Publication date: May 3, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lisha Wang, Hongying Yun, Xiufang Zheng
  • Publication number: 20180093999
    Abstract: The present invention relates to compounds of formula (I), wherein R1 to R5 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: November 10, 2017
    Publication date: April 5, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Baoxia Wang, Lisha Wang, Hongying Yun, Xiufang Zheng
  • Publication number: 20180072730
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: August 29, 2017
    Publication date: March 15, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lu Gao, Chungen Liang, Hongying Yun, Xiufang Zheng, Jianping Wang, Kun Miao, Bo Zhang
  • Publication number: 20180072726
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, W1, W2, W3, A and X are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: November 16, 2015
    Publication date: March 15, 2018
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Lisha WANG, Lu GAO, Mengwei HUANG, Lei GUO, Chungen LIANG, Wei ZHU, Song FENG, Xiufang ZHENG, Weixing ZHANG, Guolong WU, Baoxia WANG, Hongying YUN
  • Publication number: 20180072725
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, W and X are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: November 20, 2017
    Publication date: March 15, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: LISHA WANG, HONGYING YUN, WEIXING ZHANG, XIUFANG ZHENG
  • Patent number: 9890155
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, W and X are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: February 13, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Lisha Wang, Hongying Yun, Weixing Zhang, Xiufang Zheng
  • Publication number: 20170275286
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: June 13, 2017
    Publication date: September 28, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Chungen Liang, Jianping Wang, Kun Miao, Hongying Yun, Xiufang Zheng
  • Patent number: 9708325
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: July 18, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Chungen Liang, Jianping Wang, Kun Miao, Hongying Yun, Xiufang Zheng
  • Patent number: 9670211
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, W and X are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: June 6, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Lu Gao, Lei Guo, Chungen Liang, Baoxia Wang, Lisha Wang, Hongying Yun, Weixing Zhang, Xiufang Zheng
  • Publication number: 20160326177
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: May 6, 2016
    Publication date: November 10, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Chungen Liang, Jianping Wang, Kun Miao, Hongying Yun, Xiufang Zheng
  • Publication number: 20160326209
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: July 11, 2016
    Publication date: November 10, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Dongdong Chen, Song Feng, Lu Gao, Chao Li, Baoxia Wang, Lisha Wang, Hongying Yun, Xiufang Zheng